GILEAD SCIENCES, INC. Research and Development in Process
GILEAD SCIENCES, INC. (GILD) reported Research and Development in Process of $481.00 million for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-03.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentInProcess · last filed 2023-05-03
- GILEAD SCIENCES, INC. research and development in process for the quarter ending 2023-03-31 was $481.00M, a 5912.50% increase year-over-year.
- GILEAD SCIENCES, INC. research and development in process for the quarter ending 2022-12-31 was $158.00M, a 76.38% decline year-over-year.
- GILEAD SCIENCES, INC. research and development in process for the quarter ending 2022-09-30 was $448.00M, a 589.23% increase year-over-year.
- GILEAD SCIENCES, INC. research and development in process for the quarter ending 2022-06-30 was $330.00M, a 139.13% increase year-over-year.
- GILEAD SCIENCES, INC. research and development in process for fiscal 2022 was $944.00M, a 0.53% increase from fiscal 2021.
- GILEAD SCIENCES, INC. research and development in process for fiscal 2021 was $939.00M, a 84.27% decline from fiscal 2020.
- GILEAD SCIENCES, INC. research and development in process for fiscal 2020 was $5.97B, a 40.39% increase from fiscal 2019.
- GILEAD SCIENCES, INC. research and development in process for fiscal 2019 was $4.25B.
| Period end | Research and Development in Process 3 month | Research and Development in Process 3 month as first filed | Research and Development in Process 6 month | Research and Development in Process 6 month as first filed | Research and Development in Process 9 month | Research and Development in Process 9 month as first filed | Research and Development in Process 12 month | Research and Development in Process 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2023-03-31 | $481.00M 10-Q · filed 2023-05-03 | $639.00M derived: sum of 2 quarters · filed 2023-05-03 | $1.09B derived: sum of 3 quarters · filed 2023-05-03 | $1.42B derived: sum of 4 quarters · filed 2023-05-03 | ||||
| 2022-12-31 | $158.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $606.00M derived: sum of 2 quarters · filed 2023-02-22 | $936.00M derived: sum of 3 quarters · filed 2023-02-22 | $944.00M 10-K · filed 2023-02-22 | ||||
| 2022-09-30 | $448.00M 10-Q · filed 2022-11-02 | $778.00M derived: sum of 2 quarters · filed 2022-11-02 | $786.00M 10-Q · filed 2022-11-02 | $1.46B derived: sum of 4 quarters · filed 2023-05-03 | ||||
| 2022-06-30 | $330.00M 10-Q · filed 2022-08-08 | $338.00M 10-Q · filed 2022-08-08 | $1.01B derived: sum of 3 quarters · filed 2023-05-03 | $1.07B derived: sum of 4 quarters · filed 2023-05-03 | ||||
| 2022-03-31 | $8.00M 10-Q · filed 2023-05-03 | $0.00 10-Q · filed 2022-05-04 | $677.00M derived: sum of 2 quarters · filed 2023-05-03 | $742.00M derived: sum of 3 quarters · filed 2023-05-03 | $880.00M derived: sum of 4 quarters · filed 2023-05-03 | |||
| 2021-12-31 | $669.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $734.00M derived: sum of 2 quarters · filed 2023-02-22 | $872.00M derived: sum of 3 quarters · filed 2023-02-22 | $939.00M 10-K · filed 2023-02-22 | $177.00M 10-K · filed 2022-02-23 | |||
| 2021-09-30 | $65.00M 10-Q · filed 2022-11-02 | $19.00M 10-Q · filed 2021-11-03 | $203.00M derived: sum of 2 quarters · filed 2022-11-02 | $270.00M 10-Q · filed 2022-11-02 | $177.00M 10-Q · filed 2021-11-03 | $441.00M derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-06-30 | $138.00M 10-Q · filed 2022-08-08 | $96.00M 10-Q · filed 2021-08-05 | $205.00M 10-Q · filed 2022-08-08 | $158.00M 10-Q · filed 2021-08-05 | $376.00M derived: sum of 3 quarters · filed 2023-02-22 | $1.55B derived: sum of 4 quarters · filed 2023-02-22 | ||
| 2021-03-31 | $62.00M 10-Q · filed 2022-05-04 | $238.00M derived: sum of 2 quarters · filed 2023-02-22 | $1.41B derived: sum of 3 quarters · filed 2023-02-22 | $5.93B derived: sum of 4 quarters · filed 2023-02-22 | ||||
| 2020-12-31 | $176.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22 | $1.35B derived: sum of 2 quarters · filed 2023-02-22 | $5.87B derived: sum of 3 quarters · filed 2023-02-22 | $5.97B 10-K · filed 2023-02-22 | $5.86B 10-K · filed 2021-02-25 | |||
| 2020-09-30 | $1.17B 10-Q · filed 2021-11-03 | $5.70B derived: sum of 2 quarters · filed 2021-11-03 | $5.79B 10-Q · filed 2021-11-03 | $5.79B derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-06-30 | $4.52B 10-Q · filed 2021-08-05 | $4.62B 10-Q · filed 2021-08-05 | $4.62B derived: sum of 3 quarters · filed 2022-02-23 | $8.58B derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2020-03-31 | $97.00M 10-Q · filed 2021-05-06 | $97.00M derived: sum of 2 quarters · filed 2022-02-23 | $4.06B derived: sum of 3 quarters · filed 2022-02-23 | $4.22B derived: sum of 4 quarters · filed 2022-02-23 | ||||
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-23 | $3.96B derived: sum of 2 quarters · filed 2022-02-23 | $4.13B derived: sum of 3 quarters · filed 2022-02-23 | $4.25B 10-K · filed 2022-02-23 | ||||
| 2019-09-30 | $3.96B 10-Q · filed 2020-11-04 | $4.13B derived: sum of 2 quarters · filed 2020-11-04 | $4.25B 10-Q · filed 2020-11-04 | |||||
| 2019-06-30 | $165.00M 10-Q · filed 2020-08-06 | $291.00M 10-Q · filed 2020-08-06 | ||||||
| 2018-12-31 | $0.00 10-K · filed 2021-02-25 | |||||||
| 2009-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2010-03-01 | $0.00 derived: sum of 2 quarters · filed 2010-03-01 | $0.00 derived: sum of 3 quarters · filed 2010-03-01 | $0.00 10-K · filed 2010-03-01 | ||||
| 2009-09-30 | $0.00 10-Q · filed 2009-11-05 | $0.00 derived: sum of 2 quarters · filed 2009-11-05 | $0.00 10-Q · filed 2009-11-05 | $0.00 derived: sum of 4 quarters · filed 2011-02-28 | ||||
| 2009-06-30 | $0.00 10-Q · filed 2009-08-05 | $0.00 10-Q · filed 2009-08-05 | $0.00 derived: sum of 3 quarters · filed 2011-02-28 | $0.00 derived: sum of 4 quarters · filed 2011-02-28 | ||||
| 2009-03-31 | $0.00 derived: 10-K 12 month − 3 quarters · filed 2010-03-01 | $0.00 derived: sum of 2 quarters · filed 2011-02-28 | $0.00 derived: sum of 3 quarters · filed 2011-02-28 | $10.85M derived: sum of 4 quarters · filed 2011-02-28 | ||||
| 2008-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2011-02-28 | $0.00 derived: sum of 2 quarters · filed 2011-02-28 | $10.85M derived: sum of 3 quarters · filed 2011-02-28 | $10.85M 10-K · filed 2011-02-28 | ||||
| 2008-09-30 | $0.00 10-Q · filed 2009-11-05 | $10.85M derived: sum of 2 quarters · filed 2009-11-05 | $10.85M 10-Q · filed 2009-11-05 | |||||
| 2008-06-30 | $10.85M 10-Q · filed 2009-08-05 | $10.85M 10-Q · filed 2009-08-05 | ||||||
| 2007-12-31 | $0.00 10-K · filed 2010-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |